Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 0 | 1,986 | 2,302 | 2,022 | 1,788 |
| Gross Profit | N/A | 1,986 | 2,302 | 2,022 | 1,788 |
| Operating Expenses | 34,024 | 28,739 | 23,723 | 21,954 | 27,686 |
| Operating Income | -34,024 | -26,753 | -21,421 | -19,932 | -25,898 |
| Interest Expense | 15 | 17 | 19 | 22 | 24 |
| Other Income | 1,306 | -112 | -89 | 1,169 | 398 |
| Pre-tax Income | -32,733 | -26,882 | -21,529 | -18,785 | -25,524 |
| Net Income Continuous | -32,733 | -26,882 | -21,529 | -18,785 | -25,524 |
| Net Income | $-32,733 | $-26,882 | $-21,529 | $-18,785 | $-25,524 |
| EPS Basic Total Ops | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 |
| EPS Basic Continuous Ops | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 |
| EPS Diluted Total Ops | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 |
| EPS Diluted Continuous Ops | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 |
| EPS Diluted Before Non-Recurring Items | -0.09 | -0.09 | -0.08 | -0.07 | -0.09 |
| EBITDA(a) | $-33,738 | $-26,476 | $-21,138 | $-19,628 | $-25,604 |